大行评级丨花旗：上调上海医药目标价至14.2港元 维持“买入”评级

Core Viewpoint - Citigroup has raised the target price for Shanghai Pharmaceuticals from HKD 13.1 to HKD 14.2, citing that the market may underestimate the long-term value created by the company's manufacturing platform restructuring, the significant potential of the commercial insurance market, and clear progress in cost optimization [1] Group 1 - The revenue forecasts for Shanghai Pharmaceuticals for 2025 to 2027 have been lowered by 3% to 6% to reflect ongoing pressure on core business [1] - The earnings per share forecasts for the same period have been reduced by 12% to 14% [1] - Citigroup maintains a "Buy" rating for Shanghai Pharmaceuticals [1]